ProMetic Life Sciences Inc. (TSE:PLI) is scheduled to be posting its quarterly earnings results after the market closes on Monday, August 14th.

Shares of ProMetic Life Sciences Inc. (TSE:PLI) traded down 0.314% during mid-day trading on Wednesday, reaching $1.585. 70,580 shares of the company’s stock were exchanged. The stock’s market cap is $1.06 billion. ProMetic Life Sciences Inc. has a one year low of $1.45 and a one year high of $3.24. The company has a 50 day moving average price of $1.64 and a 200-day moving average price of $2.04.

PLI has been the topic of a number of analyst reports. Canaccord Genuity decreased their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Royal Bank Of Canada restated an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday, May 24th. Finally, Scotiabank decreased their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research report on Friday, July 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of C$4.37.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at

In other ProMetic Life Sciences news, Director Louise Ménard sold 82,202 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of C$1.60, for a total value of C$131,523.20. Insiders acquired 28,424 shares of company stock worth $56,809 in the last 90 days.

About ProMetic Life Sciences

ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer.

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with's FREE daily email newsletter.